MedTrace Logo

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

NCT03876886 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-03-21

No results posted yet for this study

Summary

The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer with homologous recombination repair deficiency.

The other purpose of this trial is to observe the patient's tolerance.

Conditions

Interventions

DRUG

Epirubicin

Epirubicin 90mg/m2 iv d1 or divide into two days

DRUG

Cyclophosphamide

cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih

DRUG

Paclitaxel

paclitaxel 175mg/m2 iv d1, q14d\*4cycles

DRUG

Carboplatin

carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih

DRUG

Paclitaxel

paclitaxel 175mg/m2 iv d1, q14d\*8cycles

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-22
Primary Completion
2024-02-29
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03876886 on ClinicalTrials.gov